Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, demonstrated up to 56.2% greater relative reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback